Rubbish Check
CNBC Top News · 29 July 2026
source“Hims and Hers shares fall 10% as FTC sues company over data, billing practices”
R2/ 10
Lightly altered
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates CNBC's headline that Hims & Hers stock fell 10% as the FTC sued over data and billing practices a 2/10, because the FTC's own press release and multiple wire reports confirm the same core allegations, with only the stock-drop percentage varying slightly (10-12%) depending on the moment of the intraday trade.
The Verdict
Lightly altered. This is close to the base fact: a real lawsuit, filed the same day, alleging the exact three things CNBC names (data sharing, billing, cancellation practices). The only wobble is the stock-fall figure, a live number that moved during the trading day rather than a chosen frame.
What actually happened
The FTC, joined by Los Angeles County and Utah, sued Hims & Hers Health, alleging the telehealth company shared users' sensitive health data with advertisers like Meta and Snap despite promising privacy, charged customers before a medical consultation, and made cancellation difficult. The Federal Trade Commission, joined by Utah and California, by and through Los Angeles County Counsel, sued Hims & Hers alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices. Hims & Hers denies the claims and says it will fight them.
Key facts
- FTC lawsuit filed 29 July 2026, joined by Los Angeles County and Utah, alleging deceptive data-sharing, billing, and cancellation practices, per the FTC's own release.
- Reuters reported the stock Hims & Hers stock added to losses after the news and was trading down around 12%, while CNBC's headline figure was 10%; Investing.com also reported Hims & Hers Health (NYSE:HIMS) shares fell 12% Wednesday, meaning CNBC's number likely reflects an earlier snapshot in a still-moving session.
- FTC investigation into the company dates back to October 2023, with a $15 million probable-loss accrual disclosed by Hims & Hers in May.
- Billing allegation specifics: Hims & Hers also starts charging users for prescriptions before they have had a chance to meet with healthcare providers, the spokesperson said.
What to watch for
- Hims & Hers reports quarterly earnings on 10 August; watch for how the company frames legal exposure and whether it updates the $15 million accrual.
- The lawsuit runs alongside a separate DOJ referral over GLP-1 compounding and a Novo Nordisk suit, none of which CNBC's headline mentions, worth tracking for cumulative legal risk.
- Confirm final closing-price move versus the intraday 10-12% range cited across outlets once markets settle.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
Related
